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Abstract: In this work, 13 jet nebulizers, some of which in different configurations, were investigated
in order to identify the biopharmaceutical constraints related to the quality attributes of the medicinal
products, which affect their safety, efficiency, compliance, and effectiveness. The aerosolization
parameters, including the aerosol output, aerosol output rate, mass median aerodynamic diameter,
and fine particle fraction, were determined according to the European Standard EN 13544-1,
using sodium fluoride as a reference formulation. A comparison between the aerosol output
nebulization time and the fine particle fraction displayed a correlation between the aerosol quality
and the nebulization rate. Indeed, the quality of the nebulization significantly increased when the rate
of aerosol emission was reduced. Moreover, the performance of the nebulizers was analyzed in terms
of respirable delivered dose and respirable dose delivery rate, which characterize nebulization as the
rate and amount of respirable product that could be deposited into the lungs. Depending on which of
these two latter parameters was used, the nebulizers showed different performances. The differences,
in terms of the rate and amount of delivered aerosol, could provide relevant information for the
appropriate choice of nebulizer as a function of drug product, therapy, and patient characteristics.
Keywords: nebulizers; aerosol output rate; aerosol output; mass median aerodynamic diameter;
fine particle fraction; respirable dose delivery rate; respirable delivered dose
1. Introduction
Nebulization is the oldest technique for the pulmonary administration of active substances using
aerosol [1]. From the old vaporization devices to the recent full technology apparatuses, the objective
still remains the generation of a proper aerosol and the deposition of an adequate drug dose in the
lungs at the appropriate site and within a convenient time [2–4].
Nebulizers, as equipment (hardware), are primarily designed in terms of technical solutions,
with the goal of assuring a predictable and reproducible aerosolization performance [4]. However,
their use in drug therapy has important biopharmaceutical objectives. In the case of local or systemic
drug activity, aerosol delivery and deposition on the lung epithelium leads to drug absorption. Therefore,
nebulization products present in vitro characteristics related to their pharmaceutical development and
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in vivo properties linked to aerosol deposition and drug absorption [4,5]. Consequently, bioavailability
parameters also have to be viewed as objectives of each drug product nebulization.
This in vitro and in vivo relationship reminds that inhalation products are the result of separated
industrial competencies arising from a combination of the device and the formulated medicinal
product. In the case of nebulization products, the combination consists of the nebulizer and the
drug formulation. Both components account for efficacy by determining the availability (disposition)
of the active substance [6–11]. The major barriers created by this combination derive from the
fact that the manufacturers belong to different industrial sectors, i.e., the mechanical and the
pharmaceutical industry [12–14]. They do not necessarily have the same product objectives. However,
drug administration by nebulization merges these two different industrial competencies (i.e., know-how
in formulation and the device) toward the final objective of the therapy’s success. For example,
nebulization products for chronic and rare diseases are available on the market for coupling with
a dedicated tested nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has
been reported [8,19–24].
In this study, the pharmaceutical aspects of the nebulization process are explored to identify the
biopharmaceutical constraints related to the quality attributes of medicinal products in order to assure
their safety, efficiency, compliance, and effectiveness. The performance of a nebulizer in the inhalation
of a drug solution or suspension was characterized by aerosol output (AO), aerosol output rate (AOR),
mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle
fraction (FPF) parameters. The determination of these characteristics allows for a prediction of the
amount of active substance that could be deposited in the respiratory tract [25].
In this work, the aerosolization performances of a previously selected number of jet nebulizers [26]
were assessed by adopting various setting conditions and using sodium fluoride as a reference
formulation, as indicated by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the
biopharmaceutical significance of the measured parameters is discussed.
2. Materials and Methods
2.1. Materials
The materials used were sodium fluoride (NaF, ACS reagent ≥ 99%, batch MKBK1961V,
Sigma Aldrich, Milan, Italy); total ionic strength adjustment buffer (TISAB) III solution (Merck
KGaA, Darmstadt, Germany); a Type A/E glass filter 76 mm in diameter with a retention capacity
of 99.98% (Pall Corporation, Port Washington, NY, USA) for the AO and AOR determinations;
and Whatman Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE Healthcare UK Limited,
Buckinghamshire, UK) for the aerodynamic assessment.
The commercial jet nebulizers used in this study are summarized in Table 1. Each compressor
was connected to an ampoule. In some cases, as reported in Table 1, the ampoule could be used in
different configurations.
2.2. Methods
2.2.1. Determination of AOR and AO
Aerosol output rate (AOR) and aerosol output (AO) values were determined according to the
European Standard EN 13544-1: 2007 + A1: 2009. For the aspiration of the aerosol, a sine pump (Model
SRU500CC, VCS, Parma, Italy) that reproduced the respiratory act through inhalation/exhalation was
used. The volume of air moved was 500 mL with a cycle of 15 respiratory acts per minute and with
a ratio of inhalation/exhalation equal to 1. The nebulization time for the AOR was 1 min, while the
nebulization time for the AO was 1 min after the “sputtering”. An NaF solution in distilled water was
prepared at a 1% (w/v) final concentration. The experiments were carried out in triplicate.
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The determination of the AOR was performed as follows: the outlet of the nebulizer system
equipped with a silicone rubber adapter was connected to the filter and its holder, and the latter to
the sine pump. The ampoule was filled with 2 mL of the 1% (w/v) NaF solution (to be nebulized).
The pump was switched on, and, 10 s later, so was the nebulizer. After 1 min, the nebulizer was
switched off, and 5 s later, the sine pump was, too. The filter, the filter holder, and the dismountable
connector from the outlet of the nebulizer system to the filter holder were dismantled. The amount of
sodium fluoride in the components from the outlet of the nebulizer to the filter, included, was extracted
and measured. The washing waters were transferred into 50-mL volumetric flasks containing 5 mL of
TISAB III solution and were brought to volume with distilled water. Prior to this, the filter was wetted
in the crystallizer with distilled water and sonicated for 5 min to favor NaF recovery.
The concentration of NaF in the volumetric flasks was determined in mV using an ion-selective
electrode (Crison Strumenti S.p.A., Carpi, MO, Italy) connected to the potentiometer (pH meter Crison
GPL21 S/N 145024 (Crison Instruments S.p.A., Carpi, MO, Italy)).
An analysis for the determination of the AO was carried out following the procedure described
above, except for the nebulization time. The aerosol was collected in the filter inside the filter holder
from the beginning of nebulization until one minute after the sputtering.
Table 1. List of the pneumatic nebulizers used in this study.
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color
Pari Compact Pari 2W17C10078 White
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assure their safety, efficiency, compliance, and effectiveness. The performance of a nebulizer in the 
inhalation of a drug solution or suspension was characterized by aerosol output (AO), aerosol output 
rate (AOR), mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and 
fine particle fraction (FPF) parameters. The determination of these characteristics allows for a 
prediction of the amount of active substance that could be deposited in the respiratory tract [25]. 
In this work, the aerosolization performa ces of a previously selected number of jet nebulizers 
[26] were assessed by adopting various setting conditions and using sodium flu ride as a reference 
formulation, as indicated by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
biopharmaceutical significance of the measured parameters is discussed. 
2. Materials and Methods 
2.1. Materials 
The materials used were sodium fluoride (NaF, ACS reagent ≥ 99%, batch MKBK1961V, Sigma 
Aldrich, Milan, Italy); total ionic strength adjustment buffer (TISAB) III solution (Merck KGaA, 
Darmstadt, Germany); a Type A/E glass filter 76 mm in diameter with a retention capacity of 99.98% 
(Pall Corporation, Port Washington, NY, USA) for the AO and AOR determinations; and Whatman 
Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE Healthcare UK Limited, 
Buckinghamshire, UK) for the aerodynamic assessment. 
The commercial jet nebulizers used in this study are summarized in Table 1. Each compressor 
was connected to an ampoule. In some cases, as reported in Table 1, the ampoule could be used in 
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Table 1. List of the pneumatic nebulizers used in this study. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact Pari 2W17C10078  White  
Pari Compact Junior Pari 2W17A13163  Light green  
Pari Boy SX Pari 2W17B01844 
Blue Pisper * Blue  
Red Pisper * Red  
Pari JuniorBoy SX Pari 2W17B08883  Orange  
Pari TurboBoy SX Pari 2W16H00598  Yellow  
Microdrop Family 2 Flaem Nuova 16A 155 0873  Light blue  
Microdrop Calimero 2 Flaem Nuova 16AF450652 
Ampoule Valve MAX Brown  
Ampoule Valve MIN Purple  
Microdrop Pro 2 Flaem Nuova 15 A7870439 
Ampoule Valve MAX Fuchsia  
Ampoule Valve MIN Grey  
Pari Compact Junior Pari 2W17A13163 Light green
Pharmaceutics 2019, 11, x FOR PEER REVIEW 2 of 10 
 
Therefore, nebulization products present in vitro characteristics related to their pharmaceutical 
development and in vivo properties linked to aerosol deposition and drug absorption [4,5]. 
Consequently, bioavailability parameters also have to be viewed as objectives of each drug product 
nebulization. 
This in vitro and in vivo relationship reminds that inhalation products are the result of separated 
industrial competencies arising from a combination of the device and the formulated medicinal 
product. In the case of nebulization products, the combination consists of the nebulizer and the drug 
formulation. Both components account for efficacy by determining the availability (disposition) of 
the active substance [6–11]. The major barriers created by this combination derive from the fact that 
the manufacturers belong to different industrial sectors, i.e., the mechanical and the pharmaceutical 
industry [12–14]. They do not necessarily have the same product objectives. However, drug 
administration by nebulization merges these two different industrial competencies (i.e., know-how 
in formulation and the device) toward the final objective of the therapy’s success. For example, 
nebulization products for chronic and rare diseases are available on the market for coupling with a 
dedicated tested nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has 
been reported [8,19–24]. 
In this study, the pharmaceutical aspects of the nebulization process are explored to identify the 
biopharmaceutical constraints related to the quality attributes of medicinal products in order to 
assure their safety, efficiency, compliance, and effectiveness. The performance of a nebulizer in the 
inhalation of a drug solution or suspension was characterized by aerosol output (AO), aerosol output 
rate (AOR), mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and 
fine particle fraction (FPF) parameters. The determination of these characteristics allows for a 
prediction of the amount of active substance that could be deposited in the respiratory tract [25]. 
In this work, the aerosolization performances of a previously selected number of jet nebulizers 
[26] were assessed by adopting various setting conditions and using sodium fluoride as a reference 
formulation, as indicated by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
biopharmaceutic l significa ce of the me sured parameters is discussed. 
2. Materials and Methods 
2.1. Materials 
The materials used were sodium fluoride (NaF, ACS reagent ≥ 99%, batch MKBK1961V, Sigma 
Aldrich, Milan, Italy); total ionic strength adjustment buffer (TISAB) III solution (Merck KGaA, 
Darmstadt, Germany); a Type A/E glass filter 76 mm in diameter with a retention capacity of 99.98% 
(Pall Corporation, Port Washington, NY, USA) for the AO and AOR determinations; and Whatman 
Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE Healthcare UK Limited, 
Buckinghamshire, UK) for the aerodynamic assessment. 
The commercial jet nebulizers used in this study are summarized in Table 1. Each compressor 
was co nected to an ampoule. In some cases, as reported in Table 1, the ampoule could be used in 
different configurations. 
Table 1. List of the pneumatic nebulizers used in this study. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact Pari 2W17C10078  White  
Pari Compact Junior Pari 2W17A 3163  Light gr en  
Pari Boy SX Pari 2W17B01844 
Blue Pisper * Blue  
Red Pisper * Red  
Pari JuniorBoy SX Pari 2W17B08883  Orange  
Pari TurboBoy SX Pari 2W16H00598  Yellow  
Microdrop Family 2 Flaem Nuova 16A 155 0873  Light blue  
Microdrop Calimero 2 Flaem Nuova 16AF450652 
Ampoule Valve MAX Brown  
Ampoule Valve MIN Purple  
Microdrop Pro 2 Flaem Nuova 15 A7870439 
Ampoule Valve MAX Fuchsia  
Ampoule Valve MIN Grey  
Pari Boy SX Pari 2W17B01844
Blue * Blu
Pharmaceutics 2019, 11, x FOR PEER REVIEW 2 of 10 
 
Therefore, nebulization products present in vitro characteristics related to their pharmaceutical 
development and in vivo properties linked to aerosol deposition and drug absorption [4,5]. 
Consequently, bioavailability parameters also have to be viewed as objectives of each drug product 
nebulization. 
This in vitro and in vivo relationship reminds that inhalation products are the result of separated 
industrial competencies arising from a combination of the device and the formulated medicinal 
product. In the case of nebulization products, the combination consists of the nebulizer and the drug 
formulation. Both components account for efficacy by determining the availability (disposition) of 
the active substance [6–11]. The major barriers created by this combination derive from the fact that 
the manufacturers belong to different industrial sectors, i.e., the mechanical and the pharmaceutical 
industry [12–14]. They do not necessarily have the same product objectives. However, drug 
administration by nebulization merges these two different industrial competencies (i.e., know-how 
in formulation and the device) toward the final objective of the therapy’s success. For example, 
nebulization products for chronic and rare diseases are available on the market for coupling with a 
dedicated tested nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has 
been reported [8,19–24]. 
In this study, the pharmaceutical aspects of the nebulization process are explored to identify the 
biopharmaceutical constraints related to the quality attributes of medicinal products in order to 
assure their safety, efficiency, compliance, and effectiveness. The performance of a nebulizer in the 
inhalation of a drug solution or suspension was characterized by aerosol output (AO), aerosol output 
rate (AOR), mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and 
fine pa ticle fraction (FPF) parameters. The d terminati n of t se characteristics allows for a 
prediction of the amount of active substance that could be deposited in the respiratory tract [25]. 
In this work, the aerosolization performances of a previously selected number of jet nebulizers 
[26] were assessed by adopting various setting conditions and using sodium fluoride as a reference 
formulation, as indicated by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
biopharmaceutical significance of the measured parameters is discussed. 
2. Materials and Methods 
2.1. Materials 
The materials used were sodium fluoride (NaF, ACS reagent ≥ 99%, batch MKBK1961V, Sigma 
Aldrich, Milan, Italy); total ionic strength adjustment buffer (TISAB) III solutio  (Merck KGaA, 
Darmstadt, Ger any); a Type A/E glass filter 76 mm i  diameter with a retention capacity of 99.98% 
(Pall Corporation, Port Washington, NY, USA) for the AO and AOR determinations; and Whatman 
Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE Healthcare UK Limited, 
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Table 1. List of the pneumatic nebulizers used in this study. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact Pari 2 17C10078  White  
Pari Compact Junior Pari 2W17A13163  Light green  
Pari Boy SX Pari 2W17B01844 
Blue Pisper  Blue  
Red Pisper * Red  
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Pari TurboBoy SX Pari 2W16H00598  Yellow  
Microdrop Family 2 Flaem Nuova 16A 155 0873  Light blue  
Microdrop Calimero 2 Flaem Nuova 16AF450652 
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2.1. Materials 
T e materials used were sodium fluoride (NaF, ACS reagent ≥ 99%, batch MKBK1961V, Sigma 
Aldrich, Milan, Ital ; total ionic strength adjust e t buff r (TISAB) III solution (Merck KGaA, 
D rmstadt, Germany); a Type A/E glass filter 76 mm in diameter with a retention capacity of 99.98% 
(P ll Corpo at on, Por  Washington, NY, USA) for the AO and AOR determinations; and Whatman 
Glass Micr fiber fil s 934-AHTM 82.6 mm in diameter (GE Healthcare UK Limited, 
Bu kinghamshire, UK) for the aerodynamic as e sment. 
The commercial jet nebulizer  us d in this study are summarized in Table 1. Each compr ssor 
was co nected to an ampoule. In some cases, as reported in Table 1, the ampoule could be used in 
different configurations. 
Table 1. List of the pneumatic nebulizers used i  this s udy. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact Pari 2 17C10078  White  
Pari Compact Junior Pari 2 17A13163  Light green  
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Blue Pisper * Blue  
Red Pis   Red  
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poule alve AX Fuchsia  
Ampoule Valve MIN Grey  
Pari JuniorBoy SX Pari 2W17B08883 Orange
Pharmaceutics 2019, 11, x FOR PEER REVIEW 2 of 10 
 
Therefore, ebulization products pr sent in vitro characteristics related to their pharmaceutical 
development and in vivo properties linked to aerosol deposition and drug absorption [4,5]. 
Consequently, bioavailability parameters also have to be viewed as objectives of each drug product 
nebulization. 
Th s in vitro and n vivo relationship re inds that inhalation products are the result of separated 
industrial compet ncies arising from a combination of the device and the formulated medicinal 
prod ct. In the case f nebulization products, the ombina ion consis s of the nebulizer and the drug 
formulation. Both components account for effi acy by de ermining the availability (disposition) of 
 active substance [6–11]. The major barrie s created by this co bin tion derive from the fact h t 
the manufacturers belong to different industrial s ctors, i.e., the mechanical and the pharmaceutical 
industry [12–14]. They do not nec sarily have th  same product objectives. However, drug 
administr  by nebulization merges these two diff rent industrial competen ies (i.e., know-how 
in formulation and he device) toward the fin l objecti e of the therapy’s success. For example, 
n bulization products for chronic and rare diseases are available on the market for coupling wit  a 
d dicated t sted nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has 
been reported [8,19–24]. 
In this st dy, the pharmaceutical aspects of the nebulization process are ex l red o dentify the 
biopharmaceutical constraints related to the quality attributes of medicinal products in o der to 
assure their s fety, efficiency, com liance, and effectiv ness. The performance of a nebulizer in the 
inhalation of a drug solution r suspension was characterized by ae osol output (AO), aerosol output 
rat  (AOR), mass median aerodynamic diam ter (MMAD), geome ric standard deviation (GSD), and 
fine particle fraction (FPF) parameters. The determination f these cha acte istics allows for a 
prediction of the amount f active substance that could be depo ited in he respiratory tract [25]. 
In this work, the er solization performan es of a previously selected number of jet nebulizers 
[26] were asse sed by adopting various setting conditions and using sodium fluoride s a referenc  
formulation, as indicated by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
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Table 1. List of the pneum tic nebulizers used in this study. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact Pari 2 17C10078  White  
Pari Compact Junior Pari 2 17A13163  Light green  
Pari Boy SX Pari 2 17B01844 
Blue Pisper * Blue  
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poule alve AX Fuchsia  
Ampoule Valve MIN Grey  
Pari Turb Boy SX Pari 2W H00 9 Yello
P armaceutics 2019, 11, x FOR PEER REVIEW 2 of 10 
 
Therefore, ebulization products pr sent in vitro characteristics related to their pharmaceutical
development and in vivo properti s linked to aerosol deposition and drug absorption [4,5]. 
Consequently, bioavailability parameters also have to be viewed as objectives of each drug product 
nebulization. 
Th s in vitro and n vivo relationship re inds that inhalation products are the result of separated
industrial compet ncies arising from a combination of the device and the formulated medicinal
prod ct. In the case f nebulization products, the ombina ion consis s of the nebulizer and the drug
formulation. Both components account fo  effi acy by de ermining the availability (disposition) of
 active substance [6–11]. The major barrie s created by this co bin tion derive from the fact h t 
the manufacturers belong to different industrial s ctors, i.e., the mechanical and the pharmaceutical
industry [12–14]. They do not nec sarily have th  same product objectives. However, drug
administr by nebulization merges these two diff rent industrial competen ies (i.e., know-how
in formulation and he device) toward the fin l objecti e of the therapy’s success. For example,
n bulization products for chronic and rare diseases are available on the market for coupling wit  a
d dicated t sted nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has 
been reported [8,19–24]. 
In this st dy, the pharmaceutical aspects of the nebulization process are ex l red o dentify the
biopharmaceutical constraints related to the quality attributes of medicinal products in o der to
assure their s fety, efficiency, com liance, and effectiv ness. The performance of a nebulizer in the
inhalation of a drug solution r suspension was characterized by ae osol output (AO), aerosol output
rat (AOR), mass median aerodynamic diameter (MMAD), geome ric standard deviation (GSD), and
fine particle fraction (FPF) parameters. The determination f these cha acte istics allows for a 
prediction of the amount f active substance that could be depo ited in he respiratory tract [25]. 
In this work, the er solization performan es of a previously selected number of jet nebulizers
[26] were asse sed by adopting various setting conditions and using sodium fluoride s a referenc
formulation, as indicated by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
biopharmaceutical significance of the measured parameters is discussed. 
. Materials and Methods 
2.1. Materials 
T  materials used were sodium fluoride (NaF, ACS reagent ≥ 99%, batch MKBK1961V, Sigma
Aldrich, Milan, Ital total ionic strength adjust ent buff r (TISAB) III solution (Merck KGaA,
D rmstadt, Germany); a Type A/E glass filter 76 mm in diameter with a retention capacity of 99.98%
(P ll Corpo at on, Por  Washington, NY, USA) for the AO and AOR determinations; and Whatman
Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE Healthcare UK Limited, 
Buckinghamshire, UK) for the aerodynamic as e sment. 
The commercial jet nebulizer  us d in this study are summarized in Table 1. Each compr ssor 
was co nected to an ampoule. In some cases, as reported in Table 1, the ampoule could be used in 
different configurations. 
Table 1. List of the pneum tic nebulizers used in this study. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact Pari 2W17C10078  White  
Pari Compact Junior Pari 2 17A13163  Light green  
Pari Boy SX Pari 2 17B01844 
Blue Pisper * Blue  
Red Pisper * Red  
Pari JuniorBoy S  Pari 2 17B08883  Orange  
Pari TurboBoy SX Pari 2W16H00598  Yellow  
Microdrop Fa ily 2 Flae  Nuova 16A 155 0873  Light blue  
Microdrop Calimero 2 lae  a 16 F450652 
le al e  Brown  
le al e I  Purple  
Microdrop Pro 2 Flaem Nuova 15 A7870439 
poule alve AX Fuchsia  
Ampoule Valve MIN Grey  
Microdrop Family 2 Flaem Nuova 16A 155 0873 Light blue
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Therefore, ebulization products present in vitro characteristics related to their pharmaceutical
developme t and in vivo properties linked to aerosol deposition and drug absorption [4,5].
Conseque tly, bioavailability p rameters also have to be viewed as objectives of each drug roduct 
neb lization. 
Th s i  vitro and  vivo relationship re inds that i halation products are the result of separated
industrial compet ncies arising fr m a combin tion of the device and the formulated medicinal
prod ct. In the case f nebulization products, the ombination c nsis s of the nebulizer and the drug
formulation. Both components account for effi acy by de ermining the availability (disposition) of
active substance [6–11]. The major barrie s created by this co bin ti n derive from the fact h t
the manufacturers belong to different industrial s ctors, i.e., the mechanical and the pharmaceutical
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in formulation a d he device) toward the fin l objecti e of the therapy’s success. For example,
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In t is st dy, the pharmaceutical aspects of the nebulization process are ex l red o dentify t e
biopharmaceutical constraints related t  the quality attributes of medicinal products in o der to
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inhalation of a drug solution r suspension was characterized by ae osol output (AO), aerosol output
rat (AOR), mass median aerodynamic diam ter (MMAD), geome ric standard deviation (GSD), and
fine particle fraction (FPF) parameters. The determination f these cha acte istics allows for a 
prediction of the amount of active substance that could be depo ited in he respiratory tract [25]. 
In thi  ork, the er solization performan es of a pr viously selec d number of jet nebulizers
[26] were sse sed by adopting various setting conditions and using sodium fluoride s a refere c
formulation, as indicated by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
biopharmaceutical significance of the measured parameters is discussed. 
2. Materials and Methods 
2.1. Materials 
T e materials used were sodium fluoride (NaF, ACS reagent ≥ 99%, batch MKBK1961V, Sigma
Aldrich, Mil n, Ital total ionic strength adjust e t buff r (TISAB) III solution (Merck KGaA,
Darmstadt, Germany); a Type A/E glass filter 76 m in ia eter with a retention capacity of 99.98%
(P ll Corpo at on, Por  Was ington, NY, USA) for the AO and AOR determinations; and Whatman
Glass Microfiber fi ters 934-AHTM 82.6 mm in diamet r (GE He lthcare UK Limited, 
Buckinghamshire, UK) for the aerodynamic as e sment. 
The c mmercial jet nebulizer  us d in this study are summarized in Table 1. Each compr ssor
was co nected to an ampoule. In some cases, as reported in Table 1, the ampoule could be used in 
different configurations. 
Table 1. L st of the pneum tic nebulizers used in this s udy. 
Neb lize  Manufacturer Batch (S/N) Configuration Iden ification Color 
Pari Compact C10078  White  
Pari Compact Junior Pari 2 17A13163  Light green  
Pari Boy SX 7B 1844 
Blue Pisper * Blue  
Red Pisper * Red  
Pari JuniorBoy SX Pari 2 17B08 8   Orange  
Pari TurboBoy SX Pari 2W16H00598  Yellow  
Microdrop Fa ily 2 Flae  uova 16  155 0873  Light blue  
Microdrop Calimero 2 l   6 F45 652 
l  l   Brown  
l  l  I  Purple  
Microdrop Pro 2 Flaem Nuova 15 A7870439 
poule alve AX Fuchsia  
Ampoule Valve MIN Grey  
Microdrop Calimero 2 Flaem Nuova 16AF450652
Ampoule Valve Brown
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Therefor , ebulization products pr sent in vitro charact ristics related to their pharmaceutical
d velopme t and in vivo properti s linked to aerosol deposition and drug absorption [4,5].
Conseque tly, bioavailability p rameters also have to be viewed as objectives of each drug roduct 
neb lization. 
Th s i  vitro and  vivo relationship re inds that i halation products are the result of separated
industrial compet ncies arising fr m a combin tion of the device and the formulated medicinal
prod ct. In the case f nebulization products, the ombination c nsis s of the nebulizer and the drug
formulation. Both components account fo  effi acy by de ermining the availability (disposition) of
active substance [6–11]. The major b rrie s created by this co bin ti n derive from the fact h t
the manufacturers b long to different industrial s ctors, i.e., the mechanical and the pharmaceutical
i dustry [12–14]. They do not nec sarily have the same product objectives. Howev r, drug
administr by nebulization merges th se two diff rent industrial co peten ies (i.e., k ow-how
in formulation a d he device) toward the fin l objecti e of the therapy’s succ ss. For example,
n bulization products for chronic and rare diseases are available on the market for coupling wit  a
d dicated t ste  nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has 
een reported [8,19–24]. 
In t is st dy, the pharmaceutical aspects of th  nebulization process are ex l red o dentify t
biopharmaceutical constraints relat d t  the quality attributes of medicinal products in o der to
assure their s fety, fficiency, com liance, and effectiv ness. Th  performance of a nebulizer in the
inhalation of a drug solution r suspension was characterized by ae osol output (AO), aerosol output
rat (AOR), mass median aerodynamic diameter (MMAD), geome ric standard deviation (GSD), and
fine particle fraction (FPF) parameters. The d termination f th s  cha acte istics allows for a 
prediction of the amount of active substance that could be depo ited in he respiratory tract [25]. 
In this work, the r solization performan es of a previously selected number of jet nebulizers
[26] were sse sed by adopting various setting conditions and using sodium fluoride s a referenc
f rmulation, as indicated by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, nd the 
biopharmaceutical significa ce of the measur d parameters is discussed. 
2. Materials and Methods 
2.1. Materials 
T e materials used were sodium fluoride (NaF, ACS reag nt ≥ 99%, batch MKBK1961V, Sigma
Aldrich, Mil n, Ital total ionic strength adjust e t buff r (TISAB) III solution (Merck KGaA,
Darmstadt, Germany); a Type A/E glass filter 76 m in ia eter with a ret ntion capacity of 99.98%
(P ll Corpo at on, Por  Was ington, NY, USA) for the AO and AOR determinations; and Whatman
Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE He lthcare UK Limited, 
Buckinghamshire, UK) for th  aerodynamic as e sment. 
The c mmercial jet nebulizer  us d in this study are summarized in Table 1. Each compr ssor
was co nected to an ampoule. In some cases, as reported in Table 1, the ampoule could be used in 
different configurations. 
Table 1. List of the pneum tic nebulizers used in this s udy. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact C10078  White 
Pari Compact Junior A1316 Light green 
Pari Boy SX 7B 1844 
Blue Pisper * B ue 
Red Pisper * Red 
Pari JuniorBoy SX Pari 2 17B08 8   O ange 
Pari TurboBoy SX Pari 2W16H00598  Yellow
Microdrop Fa ily 2 Flae  uova 16A 155 0873  Light blue 
Microdrop Calimero 2 l   6 F45 652 
l  l   Brown 
l  l  I  Purple  
Microdrop Pro 2 Flaem Nuova 15 A7870439 
poule alve AX Fuchsia  
Ampoule Valve MIN Grey  
Ampoul l I Purple
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Therefor , ebulization products present in vitro charact ristics related to their pharmaceutical
d velopme t and in vivo properti s linked to aerosol deposition and drug absorption [4,5].
Conseque tly, bioavailability p rameters also have to be viewed as objectives of each drug roduct 
neb lization. 
Th s i  vitro and  vivo relationship re inds that i halation products are the result of separated 
industrial compet ncies arising fr m a combin tion of the device and the formulated medicinal 
prod ct. In the case f nebulization products, the ombination nsis s of the nebulizer and the drug 
formulation. Both components account fo  effi acy by de ermining the availability (disposition) of
active substance [6–11]. The ajor b rrie s created by this co bin ti n derive from the fact h t 
the manufacturers b long to different indu trial s ctors, i.e., the mechanical and the pharmaceutical 
i dustry [12–14]. They do not nec sarily have the same product objectives. Howev r, drug 
administr by nebulization merges th se two diff rent industrial co peten ies (i.e., k ow-how 
in formulation a d he device) toward the fin l objecti e of the therapy’s succ ss. For example, 
n bulization products for chronic and rare diseases are available on the market for coupling wit  a
d dicated t ste  nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has 
een reported [8,19–24]. 
In t is st dy, the pharmaceutical aspects of th  nebulization process are ex l red o dentify t  
biopharmaceutical constraints relat d t  the quality attributes of medicinal products in o der to 
assure their s fety, fficiency, com liance, and effectiv ness. Th  performance of a nebulizer in the 
inhalation of  drug solution r suspension was char cterized by ae o l output (AO), aerosol outpu  
rat (AOR), mass median aero ynamic dia eter (MMAD), geome ric standard deviatio  (GSD), and
fine particle fraction (FPF) parameters. The d termination f th s  cha acte istics allows for a 
prediction of the amount of active substance that could be depo ited in he respiratory tract [25]. 
In this work, the r solization performan es of a previously selected number of jet nebulizers 
[26] were sse sed by adopting various setting conditions and u ing sodium fluoride s a referenc
formulation, as indicate  by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
biopharmaceutical significance of the measured parameters is discussed. 
2. Mater als  M thods 
2.1. Materials 
T e materials used were sodium fluoride (NaF, ACS reag nt ≥ 99%, batch MKBK1961V, Sigma 
Aldrich, Mil n, Ital total ionic strength adjust e t buff r (TISAB) III solution (Merck KGaA, 
Darmstadt, Germany); a Type A/E glass filter 76  in dia eter with a ret ntion capacity of 99.98% 
(P ll Corpo at on, Por  Was ington, NY, USA) for the AO and AOR determinations; and Whatman
Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE He lthcare UK Limited, 
Buckinghamshire, UK) for th  aerodynamic as e sment. 
The mmercial jet nebulizer  us d in this study are summarized in Table 1. Each compr ssor
was co nected to an ampoule. In s me cases, s reported in Table 1, the ampoule could be used in 
different configurations. 
Table 1. List of the pneum tic nebulizers used in this s udy. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact C10078  White 
Pari Compact Junior  A1316   Light gr en  
Pari Boy SX 7B 1844 
Blue Pisper * B ue  
Red Pisper * Red  
Pari JuniorBoy SX Pari 2 17B08 8   O ange 
Pari TurboBoy SX Pari 2W16H00598  Yellow
Microdrop Fa ily 2 Flae  o a 16  155 0873  Light blue  
Microdrop Calimero 2 l   6 F45 652 
l  l   Brown  
l  l  I  Purple  
Microdrop Pro 2 Flaem Nuova 15 A7870439 
poule alve AX Fuchsia  
Ampoule Valve MIN Grey  Microdrop Pro 2 Flaem Nuova 15 A7870439
Ampoule Valve AX Fuchsia
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Therefor , nebulization products pr sent in vitro charact ristics related to their pharmaceutical 
d velopme t and in vivo properti s linked to aerosol deposition and drug absorption [4,5].
Conseque tly, bioavailability p rameters also have to be viewed as objectives of each drug roduct 
neb lization. 
Th s i  vitro and  vivo relationship re inds that i halation products are the result of separated 
industrial compet ncies arising fr m a combin tion of the device and the formulated medicinal 
prod ct. In the case f nebulization products, the ombination c nsis s of the nebulizer and the drug 
formulation. Both components account fo  effi acy by de ermining the availability (disposition) of 
active substance [6–11]. The ajor b rrie s created by this co bin ti n derive from the fact h t 
the manufacturers b long to different industrial s ctors, i.e., the mechanical and the pharmaceutical 
i dustry [12–14]. They do not nec sarily have the same product objectives. Howev r, drug 
administr by nebulization merges th se two diff rent industrial co peten ies (i.e., k ow-how 
in formulation a d he device) toward the fin l objecti e of the therapy’s succ ss. For example, 
n bulization products for chronic and rare diseases are available on the market for coupling wit  a
d dicated t ste  nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has 
een reported [8,19–24]. 
In t is st dy, the pharmaceutical aspects of th  nebulization process are ex l red o dentify t  
biopharmaceutical constraints relat d t  the quality attributes of medicinal products in o der to 
assure their s fety, fficiency, com liance, and effectiv ness. Th  performance of a nebulizer in the 
inhalation of a drug solution r suspension was characterized by ae osol output (AO), aerosol output 
rat (AOR), mass median aerodynamic dia eter (MMAD), geome ric standard deviation (GSD), and
fine particle fraction (FPF) parameters. The d termination f th s  cha acte istics allows for a 
prediction of the amou t of active subs ance that could be depo ited in he resp ratory tract [25]. 
In this work, the r olization erforman es of a pr viously s lected number of jet nebulizers 
[26] were sse sed by adopting various setting conditions and using sodium fluoride s a referenc
formulation, as indicate  by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
biopharmaceutical significance of the measured parameters is discussed. 
2. Materials and Methods 
2.1. Mat rials 
T e materials used were sodium fluoride (NaF, ACS reag nt ≥ 99%, batch MKBK1961V, Sigma 
Aldrich, Mil n, Ital total ionic strength adjust e t buff r (TISAB) III solution (Merck KGaA, 
Darmstadt, Germany); a Type A/E glass filter 76  in ia eter with a ret ntion capacity of 99.98% 
(P ll Corpo at o , Por  Was ington, NY, USA) for the AO and AOR determinations; and Whatman
Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE He lthcare UK Limited, 
Buckinghamshire, UK) for th  aerodynamic as e sment. 
The c mmercial jet nebulizer  us d in this study are s mmarized in Table 1. Each compr ssor
was co nected to an ampoule. In s me cases, s reported in Table 1, the ampoule could be used in 
different configurations. 
Table 1. List of the pneum tic nebulizers used in this s udy. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact C10078  White 
Pari Compact Junior  A1316   Light green  
Pari Boy SX 7B 1844 
Blue Pisper * B ue  
Red Pisper * Red  
Pari JuniorBoy SX Pari 2 17B08 8   O ange 
Pari TurboBoy SX Pari 2W16H00598  Yellow
Microdrop Fa ily 2 Flae  ova 16A 155 0873  Light blue  
Microdrop Calimero 2 l   6 F45 652 
l  l   Brown  
l  l  I  Pu ple  
Microd p Pro 2 Flaem Nuova 15 A7870439 
poule al   Fuchsia  
Ampoule Valve MIN Grey  Ampoule Valve MIN Grey
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Therefor , nebulization products present in vitro charact ristics related to their pharmaceutical 
d velopme t and in vivo properti s linked to aerosol deposition and drug absorption [4,5].
Conseque tly, bioavailability p rameters also have to be viewed as objectives of each drug roduct 
neb lization. 
Th s i  vitro and  vivo relationship re inds that i halation products are the result of separated 
industrial compet ncies arising fr m a combin tion of the device and the formulated medicinal 
prod ct. In the case f nebulization products, the ombination nsis s of the nebulizer and the drug 
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d dicated t ste  nebulizer [15–18]. In fact, variability in dose delivery from different nebulizers has 
een reported [8,19–24]. 
In t is st dy, the pharmaceutical aspects of th  nebulization process are ex l red o dentify t  
biopharmaceutical constraints relat d t  the quality attributes of medicinal products in o der to 
assure their s fety, fficiency, com liance, and effectiv ness. Th  performance of a nebulizer in the 
inhalation of a drug solution r suspension was characterized by ae o ol output (AO), aerosol output 
rat (AOR), mass median aerodynamic dia eter (MMAD), geome ric standard deviation (GSD), and
fine particle fraction (FPF) parameters. The d termination f th s  cha acte istics allows for a 
prediction of the amount of active substance that could be depo ited in he respiratory tract [25]. 
In this work, the r solization performan es of a previously selected number of jet nebulizers 
[26] were sse sed by adopting various setting conditions and u ing sodium fluoride s a referenc
formulation, as indicate  by EN 13544-1: 2007 + A1: 2009 [27]. The results were compared, and the 
biopharmaceutical s gnific nce of th  measured parameters is discussed. 
2. Materials and Methods 
2.1. Materials 
T e materials used were sodium fluoride (NaF, ACS reag nt ≥ 99%, batch MKBK1961V, Sigma 
Aldrich, Mil n, Ital total ionic strength adjust e t buff r (TISAB) III solution (Merck KGaA, 
Darmstadt, Germany); a Type A/E glass filter 76  in dia eter with a ret ntion capacity of 99.98% 
(P ll Corpo at on, Por  Was ington, NY, USA) for the AO and AOR determinations; and Whatman
Glass Microfiber filters 934-AHTM 82.6 mm in diameter (GE He lthcare UK Limited, 
Buckinghamshire, UK) for th  aerodynamic as e sment. 
The mmercial jet nebulizer  us d in this study are summarized in Table 1. Each compr ssor
was co nected to an ampoule. In s me cases, s reported in Table 1, the ampoule could be used in 
different configurations. 
Table 1. List of the pneum tic nebulizers used in this s udy. 
Nebulizer Manufacturer Batch (S/N) Configuration Identification Color 
Pari Compact C10078  White 
Pari Compact Junior  A1316   Light gr en  
Pari Boy SX 7B 1844 
Blue Pisper * B ue  
Red Pisper * Red  
Pa i JuniorBoy S  Pari 2 17B08 8   O ange 
Pari TurboBoy SX Pari 2W16H00598  Yellow
Microdrop Fa ily 2 Flae  uova 16A 155 0873  Light blue  
Microdrop Calimero 2 l   6 F45 652 
l  l   Brown  
l  l  I  Pu ple  
Microdrop Pro 2 Flaem Nuova 15 A7870439 
poule alve AX Fuchsia  
Ampoule al  I  Grey  
Microdrop Pro 2 Plus Flaem Nuova Engineering sample
Ampoule Valve MAX Dark green
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Microd p Pro 2 Plus Flaem Nuova 
Engineering 
sample 
Ampoule al   Dark gr en  
Ampoule Valve MIN Pink  
Omron C801KD Omron Healthcare 20160600989VF  Yellow-green  
Omron NE-C28P Omron Healthcare 20160905635UF  Green water  
Omron A3 Complete 3A Healthcare 201702/00279F 
Ampoule Position 1 Blush  
Ampoule Position 3 Lemon green  
Midineb Nebby 3A Healthcare 16/30635  Lilac  
* nebulizer nozzle. 
2.2. Methods 
2.2.1. Determination of AOR and AO 
Aerosol output rate (AOR) and aerosol output (AO) values were determined according to the 
European Standard EN 13544-1: 2007 + A1: 2009. For the aspiration of the aerosol, a sine pump (Model 
SRU500CC, VCS, Parma, Italy) that reproduced the respiratory act through inhalation/exhalation was 
used. The volume of air moved was 500 mL with a cycle of 15 respiratory acts per minute and with a 
ratio of inhalation/exhalation equal to 1. The nebulization time for the AOR was 1 min, while the 
nebulization time for the AO was 1 min after the “sputtering”. An NaF solution in distilled water was 
prepared at a 1% (w/v) final concentration. The experiments were carried out in triplicate. 
The determination of the AOR was performed as follows: the outlet of the nebulizer system 
equipped with a silicone rubber adapter was connected to the filter and its holder, and the latter to 
the sine pump. The ampoule was filled with 2 mL of the 1% (w/v) NaF solution (to be nebulized). The 
pump was switched on, and, 10 s later, so was the nebulizer. After 1 min, the nebulizer was switched 
off, and 5 s later, the sine pump was, too. The filter, the filter holder, and the dismountable connector 
from the outlet of the nebulizer system to the filter holder were dismantled. The amount of sodium 
fluoride in the components from the outlet of the nebulizer to the filter, included, was extracted and 
measured. The washing waters were transferred into 50-mL volumetric flasks containing 5 mL of 
TISAB III solution and were brought to volume with distilled water. Prior to this, the filter was wetted 
in the crystallizer with distilled water and sonicated for 5 min to favor NaF recovery. 
The concentration of NaF in the volumetric flasks was determined in mV using an ion-selective 
electrode (Crison Strumenti S.p.A., Carpi, MO, Italy) connected to the potentiometer (pH meter 
Crison GPL21 S/N 145024 (Crison Instruments S.p.A., Carpi, MO, Italy)). 
An analysis for the determination of the AO was carried out following the procedure described 
above, except for the nebulization time. The aerosol was collected in the filter inside the filter holder 
from the beginning of nebulization until one minute after the sputtering. 
2.2.2. Aerodynamic Assessment 
The aerodynamic parameters (MMAD, GSD, and FPF) were determined according to the 
method described in the European Standard EN 13544-1: 2007 + A1: 2009. A next-generation impactor 
(NGI, Copley S/N NGI-0497 (Copley Scientific Limited, Nottingham, UK)) was used. The 
experiments were performed in triplicate. 
The NGI was connected to an Erweka pump (model VP1000 S/N 11161406a7 (Erweka Italia 
S.R.L., Seveso, MB, Italy) via the solenoid valve of the critical flow controller (model TPK. Copley 
(Copley Scientific Limited, Nottingham, UK)). The NGI induction port was connected to the T-shaped 
glass tube using a silicone rubber adapter. A continuous aspiration flow of 15 L/min measured at the 
T-tube nebulizer port (Flowmeter Model DMF 2000; Copley Scientific Limited, Nottingham, UK) was 
applied for aerosol collection in the NGI. The mouthpiece of the ampoule, attached to the nebulizer, 
was connected to the T-shaped glass tube. The ampoule was filled with 2 mL of 2.5% (w/v) NaF 
solution. The nebulization time was fixed at 120 s, except for the nebulizers Pari Boy Sx (blue pisper) 
and Omron A3 Complete (position 1), in which it was 90 s and 45 s, respectively, due to a shorter 
sputtering time. 
The Erweka pump and the TPK valve were switched on, and after 30 s, the nebulizer was 
activated. The aerosol was collected during the predetermined nebulization time in the NGI stages 
Ampoule Valve MIN Pink
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* nebulizer nozzle. 
2.2. Methods 
2.2.1. Determination of AOR and AO 
Aerosol output rate (AOR) and aerosol output (AO) values were determined according to the 
European Standard EN 13544-1: 2007 + A1: 2009. For the aspiration of the aerosol, a sine pump (Model 
SRU500CC, VCS, Parma, Italy) that reproduced the respiratory act through inhalation/exhalation was 
used. The volume of air moved was 500 mL with a cycle of 15 respiratory acts per minute and with a 
ratio of inhalation/exhalation equal to 1. The nebulization time for the AOR was 1 min, while the 
nebulization time for the AO was 1 min after the “sputtering”. An NaF solution in distilled water was 
prepared at a 1% (w/v) final concentration. The experiments were carried out in triplicate. 
The determination of the AOR was performed as follows: the outlet of the nebulizer system 
equipped with a silicone rubber adapter was connected to the filter and its holder, and the latter to 
the sine pump. The ampoule was filled with 2 mL of the 1% (w/v) NaF solution (to be nebulized). The 
pump was switched on, and, 10 s later, so was the nebulizer. After 1 min, the nebulizer was switched 
off, and 5 s later, the sine pump was, too. The filter, the filter holder, and the dismountable connector 
from the outlet of the nebulizer system to the filter holder were dismantled. The amount of sodium 
fluoride in the components from the outlet of the nebulizer to the filter, included, was extracted and 
measured. The washing waters were transferred into 50-mL volumetric flasks containing 5 mL of 
TISAB III solution and were brought to volume with distilled water. Prior to this, the filter was wetted 
in the crystallizer with distilled water and sonicated for 5 min to favor NaF recovery. 
The concentration of NaF in the volumetric flasks was determined in mV using an ion-selective 
electrode (Crison Strumenti S.p.A., Carpi, MO, Italy) connected to the potentiometer (pH meter 
Crison GPL21 S/N 145024 (Crison Instruments S.p.A., Carpi, MO, Italy)). 
An analysis for the determination of the AO was carried out following the procedure described 
above, except for the nebulization time. The aerosol was collected in the filter inside the filter holder 
from the beginning of nebulization until one minute after the sputtering. 
2.2.2. Aerodynamic Assessment 
The aerodynamic parameters (MMAD, GSD, and FPF) were determined according to the 
method described in the European Standard EN 13544-1: 2007 + A1: 2009. A next-generation impactor 
(NGI, Copley S/N NGI-0497 (Copley Scientific Limited, Nottingham, UK)) was used. The 
experiments were performed in triplicate. 
The NGI was connected to an Erweka pump (model VP1000 S/N 11161406a7 (Erweka Italia 
S.R.L., Seveso, MB, Italy) via the solenoid valve of the critical flow controller (model TPK. Copley 
(Copley Scientific Limited, Nottingham, UK)). The NGI induction port was connected to the T-shaped 
glass tube using a silicone rubber adapter. A continuous aspiration flow of 15 L/min measured at the 
T-tube nebulizer port (Flowmeter Model DMF 2000; Copley Scientific Limited, Nottingham, UK) was 
applied for aerosol collection in the NGI. The mouthpiece of the ampoule, attached to the nebulizer, 
was connected to the T-shaped glass tube. The ampoule was filled with 2 mL of 2.5% (w/v) NaF 
solution. The nebulization time was fixed at 120 s, except for the nebulizers Pari Boy Sx (blue pisper) 
and Omron A3 Complete (position 1), in which it was 90 s and 45 s, respectively, due to a shorter 
sputtering time. 
The Erweka pump and the TPK valve were switched on, and after 30 s, the nebulizer was 
activated. The aerosol was collected during the predetermined nebulization time in the NGI stages 
Omron C801KD Omron Healthcare 2016 600989VF Yellow-green
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2.2. Methods 
2.2.1. Determination of AOR and AO 
Aerosol output rate (AOR) and aerosol output (AO) values were determined according to the 
European Standard EN 13544-1: 2007 + A1: 2009. For the aspiration of the aerosol, a sine pump (Model 
SRU500CC, VCS, Parma, Italy) that reproduced the respiratory act through inhalation/exhalation was 
used. The volume of air moved was 500 mL with a cycle of 15 respiratory acts per minute and with a 
ratio of inhalation/exhalation equal to 1. The nebulization time for the AOR was 1 min, while the 
nebulization time for the AO was 1 min after the “sputtering”. An NaF solution in distilled water was 
prepared at a 1% (w/v) final concentration. The experiments were carried out in triplicate. 
The determination of the AOR was performed as follows: the outlet of the nebulizer system 
equipped with a silicone rubber adapter was connected to the filter and its holder, and the latter to 
the sine pump. The ampoule was filled with 2 mL of the 1% (w/v) NaF solution (to be nebulized). The 
pump was switched on, and, 10 s later, so was the nebulizer. After 1 min, the nebulizer was switched 
off, and 5 s later, the sine pump was, too. The filter, the filter holder, and the dismountable connector 
from the outlet of the nebulizer system to the filter holder were dismantled. The amount of sodium 
fluoride in the components from the outlet of the nebulizer to the filter, included, was extracted and 
measured. The washing waters were transferred into 50-mL volumetric flasks containing 5 mL of 
TISAB III solution and were brought to volume with distilled water. Prior to this, the filter was wetted 
in the crystallizer with distilled water and sonicated for 5 min to favor NaF recovery. 
The concentration of NaF in the volumetric flasks was determined in mV using an ion-selective 
electrode (Crison Strumenti S.p.A., Carpi, MO, Italy) connected to the potentiometer (pH meter 
Crison GPL21 S/N 145024 (Crison Instruments S.p.A., Carpi, MO, Italy)). 
An analysis for the determination of the AO was carried out following the procedure described 
above, except for the nebulization time. The aerosol was collected in the filter inside the filter holder 
from the beginning of nebulization until one minute after the sputtering. 
2.2.2. Aerodynamic Assessment 
The aerodynamic parameters (MMAD, GSD, and FPF) were determined according to the 
method described in the European Standard EN 13544-1: 2007 + A1: 2009. A next-generation impactor 
(NGI, Copley S/N NGI-0497 (Copley Scientific Limited, Nottingham, UK)) was used. The 
experiments were performed in triplicate. 
The NGI was connected to an Erweka pump (model VP1000 S/N 11161406a7 (Erweka Italia 
S.R.L., Seveso, MB, Italy) via the solenoid valve of the critical flow controller (model TPK. Copley 
(Copley Scientific Limited, Nottingham, UK)). The NGI induction port was connected to the T-shaped 
glass tube using a silicone rubber adapter. A continuous aspiration flow of 15 L/min measured at the 
T-tube nebulizer port (Flowmeter Model DMF 2000; Copley Scientific Limited, Nottingham, UK) was 
applied for aerosol collection in the NGI. The mouthpiece of the ampoule, attached to the nebulizer, 
was connected to the T-shaped glass tube. The ampoule was filled with 2 mL of 2.5% (w/v) NaF 
solution. The nebulization time was fixed at 120 s, except for the nebulizers Pari Boy Sx (blue pisper) 
and Omron A3 Complete (position 1), in which it was 90 s and 45 s, respectively, due to a shorter 
sputtering time. 
The Erweka pump and the TPK valve were switched on, and after 30 s, the nebulizer was 
activated. The aerosol was collected during the predetermined nebulization time in the NGI stages 
Omron NE-C28P Omron Healthcare 20160905635UF Greenwater
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2.2. Methods 
2.2.1. Determination of AOR and AO 
A rosol output rate (AOR) and aerosol output (AO) values were determined according to the 
European Standard EN 13544-1: 2007 + A1: 2009. For the aspiration of the aerosol, a si e pump (Model 
SRU500CC, VCS, Parma, Italy) that reproduced the respiratory act through inhalation/exhalation was 
used. The volume of air moved was 500 mL with a cycle f 15 respiratory acts per minute and with a 
ratio of inhalation/exhalation equal to 1. The nebulization time for the AOR was 1 min, hile the 
nebulization time for the AO was 1 min after the “sputteri g”. An NaF solution in distilled water was 
prepared at a 1% (w/v) final concentration. The experiments were carried out in triplicate. 
The determinati  of the AOR was performed as f llows: the outlet of th  nebuliz r system 
equipped with a silicone rubber adapter was connected to the filter and its holder, and the latter to 
the sine pump. T e ampoule wa  fill d with 2 mL of the 1% (w/v) NaF solutio  (to be nebulized). The 
pump wa  switched o , and, 10 s later, so was th  nebulizer. After 1 min, the nebulizer was switched 
off, and 5 s later, the si  pump wa , too. The filter, t e filter holder, and the dismountable connector 
from the outl t f the ebulizer system to the filter holder were dismantled. The amount of so ium 
fluoride in the compo ents from the outlet of the nebulizer to the filt r, included, was extracted and 
measured. The washing waters were transferred into 50-mL volumetric flasks containing 5 mL of 
TISAB III olution and were brought to volume with distilled water. Prior to this, the filter was wetted 
in the crystallizer with distilled wat r and sonicated for 5 min to favor NaF recovery. 
The concentration of NaF in the volumetric flasks was d termined in mV using an ion-selective 
electrode (Crison Strumenti S.p.A., Carpi, MO, Italy) connected to the potentiometer (pH meter 
Crison GPL21 S/N 145024 (Criso  Instruments S.p.A., Carpi, MO, Italy)). 
An analysis for th  determination of the AO was carried out following the procedure described 
above, exc pt for the nebulization time. The aerosol was coll cted in the filter inside the filter holder 
from the beginning of nebulization until one minute after the sputtering. 
2.2.2. A rodynamic Assessment 
The aerodynamic param ters (MMAD, GSD, and FPF) were determined according to the 
method described in the European Standard EN 13544-1: 2007 + A1: 2009. A next-gener tion impactor 
(NGI, Copley S/N NGI-0497 (Copley Scientific Limited, Nottingham, UK)) was used. The 
experiments were performed in triplicate. 
The NGI was connected to an Erweka pump (model VP1000 S/N 11161406a7 (Erweka Italia 
S.R.L., Seveso, MB, Italy) via the solenoid valve of the criti al flow controller (mo el TPK. Copl y 
(Copley Scientific Limited, Nottingh m, UK)). The NGI induction port as connected to the T-shaped 
glass tube sing a silicone rubb r adapter. A continuous aspiration flow of 15 L/min me sured at the 
T-tub  nebulizer port (Flowmeter Model DMF 2000; Copl y Scientific Limited, Nottingham, UK) was 
applied for a ros l collection in the NGI. The mouth iece of the ampoule, attached to the nebulizer, 
was c nected to the T-shaped glass tube. The ampoule was filled with 2 mL f 2.5% (w/v) NaF 
solution. The nebulization time was fixed at 120 s, except for the nebulizers Pari Boy Sx (blue pisper) 
and Omron A3 Complete (position 1), in which it was 90 s and 45 s, respectively, due to a shorter 
sputtering time. 
The Erweka pump and the TPK valve were switched on, and after 30 s, the n bulizer wa  
activated. The aerosol was collected during the predetermined nebulization time in the NGI stages 
Omron A3 Complete 3A Healthcare 201702/00279F
Ampoule 1 Blush
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 Methods 
2.2.1. Determination of AOR and AO 
Aerosol output rate (AOR) and aerosol output (AO) values were determined according to the 
European Standard EN 13544-1: 2007 + A1: 2009. For the aspiration of the aerosol, a sine pump (Model 
SRU500CC, VCS, Parma, Italy) that reproduced the respiratory act through inhalation/exhalation was 
used. The volu e of air moved was 500 mL with a cycle of 15 respiratory acts per minute and with a 
ratio of inhalation/exhalation equal to 1. The nebulization time for the AOR was 1 min, while the 
nebulization ti e for the AO was 1 min after the “sputtering”. An NaF solution in distilled water was 
prepared at a 1% (w/v) final concentration. The experiments were carried out in triplicate. 
The determination of the AOR was performed as follows: the outlet of the nebulizer system 
equipped with a silicone rubber adapter as connected to the filter and its holder, and the latter to 
the sine pump. The ampoule was filled with 2 mL of the 1% (w/v) NaF solution (to be nebulized). The 
pu p was switched on, and, 10 s later, so was the nebulizer. After 1 in, the nebulizer was switched 
off, and 5 s later, the sine pump was, too. The filter, the filter holder, and the dismountable connector 
from the outlet of the nebulizer system to the filter holder were dismantled. The amount of sodium 
fluoride in the components from the outlet of the nebulizer to the filter, included, was extracted and 
measured. The washing waters were transferred into 50- L volumetric flasks containing 5 mL of 
TISAB III solution and were brought to volume with distilled water. Prior to this, the filter was wetted 
in the crystallizer with distilled water and sonicated for 5 min to favor NaF recovery. 
The concentration of NaF in the volumetric flasks was determined in mV using an ion-selective 
electrode (Crison Strumenti S.p.A., Carpi, MO, Italy) connected to the potentiometer (pH meter 
Crison GPL21 S/N 145024 (Crison Instruments S.p.A., Carpi, MO, Italy)). 
An analysis for the determination of the AO was carried out following the procedure described 
above, except for the nebulization time. The aerosol was collected in the filter inside the filter holder 
from th  begi ning of n buliza ion until one minute after the sputtering. 
2.2.2. A rodynamic Assessment 
The aerodynamic parameters (MMAD, GSD, and FPF) were determined according to the 
method described in the European Standard EN 13544-1: 2007 + A1: 2009. A next-generation impactor 
(NGI, Copley S/N NGI-0497 (Copley Scientific Limited, Nottingham, UK)) was used. The 
experiments were performed in triplicate. 
The NGI was connected to an Erweka pump (model VP1000 S/N 11161406a7 (Erweka Italia 
S.R.L., Seveso, MB, Italy) via the solenoid valve of the critical flow controller ( odel TPK. Copley 
(Copley Scientific Limited, Nottingham, UK)). The NGI induction port was connected to the T-shaped 
glass tube using a silicone rubber adapter. A continuous aspiration flow of 15 L/min measured at the 
T-tube nebulizer port (Flowmeter Model DMF 2000; Copley Scientific Limited, Nottingham, UK) was 
applied for aerosol collection in the NGI. The mouthpiece of the ampoule, attached to the nebulizer, 
was connected to the T-shaped glass tube. The ampoule was filled with 2 mL of 2.5% (w/v) NaF 
solution. The nebulization time was fixed at 120 s, except for the nebulizers Pari Boy Sx (blue pisper) 
and Omron A3 Complete (position 1), in which it was 90 s and 45 s, respectively, due to a shorter 
sputtering time. 
The Erweka pump and the TPK valve were switched on, and after 30 s, the nebulizer was 
activated. The aerosol was collected during the predetermined nebulization time in the NGI stages 
Ampoule Position 3 Lemongreen
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* nebulizer nozzle. 
2.2. Methods 
2.2.1. Determination of AOR and AO 
Aerosol output rate (AOR) and aerosol output (AO) valu  were determined accordi g to the
Eur pea  Standard EN 13544-1: 2007 + A1: 2009. For the aspiration f t  aerosol,  ine pump (Model 
SRU500CC, VCS, Pa ma, Italy) that reproduced the respi atory act through inhalation/exhalation  
us d. The volume of air moved was 500 mL with a cycle of 15 respiratory acts pe  minu  and with a 
ratio of inhalatio /exhalation equal to 1. The nebuliz tion time for the AOR was 1 min, while the 
nebulization time for th  AO was 1 min after the “spu tering”. An NaF solution in distilled water was
pr par d at a 1% (w/v) fina  concentration. The experiments ere c rried out in triplicate. 
The determination of the AOR was performed as follows: the outlet of the n bulizer system
equipped with a silico  r bber adapter was connect d to t e filter and its holder, and the latt r to 
the sine pump. The ampo le wa  fill d with 2 mL of the 1% (w/v) NaF solution (to be nebulized). The 
p mp was switched , and, 10 s later, so was t e li r. After 1 min, the nebulizer was switche  
off, and 5 s lat r, the si e pump was, too. The filter, the filter holder, and the dismountable connect r 
from the outlet of the nebulizer sys em to the filter holder were dismantled. The amount of sodium
fluoride in the components from th  outlet f the nebulizer to he filter, included, was extracted and 
measur d. Th  w shi g waters were transfe red into 50-mL volum tr c flasks cont ining 5 mL of
TISAB III soluti  and w re brought to volume with distilled water. Prior to this, he fil  was wetted 
in the crystallizer with distilled water and sonicated for 5 min to favor NaF recovery. 
The concentration of NaF in the volum tric flasks was etermined i  mV using an ion-selective 
electrode (Cris n Strumenti S.p.A., Carpi, MO, Italy) connected to the pote t omet r (pH met  
Crison GPL21 S/N 145024 (Crison Instruments S.p.A., Carpi, MO, Italy))
An analysis for the determination of the AO was carried out following the procedure described 
above, xcept for the nebulization time. The aerosol was collected in the filter inside the filter holder 
from the beginning of nebulization until one minute after the sputtering. 
2.2.2. A rodynamic Assessment 
The aerodynamic parameters (MMAD, GSD, and FPF) were determined according to the 
method described in the European Standard EN 13544-1: 2007 + A1: 2009. A next-generation impactor 
(NGI, Copley S/N NGI-0497 (C pley Scientific Limited, N ttingham, UK)) was used. The
experiments were performed in triplicate. 
The NGI w s con cted to n Erweka pump (model VP1000 S/N 1 161406a7 (Erweka I alia
S.R.L., S veso, MB, Italy) via the solenoid valve of the critical flow controller (model TPK. Copley 
(Copley Scientific Limit d, Nottingham, UK)). The NGI induc ion port was connected to the T-shap d 
gl s tube using a silicone rubber adap er. A continuous aspiration flo  of 15 L/min measured at the 
T-t be ebulizer port (Flow eter Mod l DMF 2000; Co ley Sci ntific Limited, Nottingham, UK) was
pplied f r aerosol col ction in the NGI. The mouthpiece of the ampoule, attached to the nebulizer,
was connected to the T-shaped glass tube. The ampoule was filled with 2 mL of 2.5% (w/v) NaF 
solution. The nebulization time was fixed at 120 s, except for the nebulizers Pari Boy Sx ( lue pisper) 
nd Omron A3 C mplete (p sition 1), in which it was 90 s and 45 s, respectively, due to a short r 
sputtering time. 
The Erweka pump and the TPK valve were switched on, and after 30 s, the nebulizer was 
activated. The aerosol was collected during the predetermined nebulization time in the NGI stages 
Midineb Nebby 3A Healthcare 16/30635 Lilac
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2.2. Meth ds 
2.2.1. Determination of AOR and AO 
Aerosol output rate (AOR) and aerosol output (AO) valu  were determined accordi g to the
Eur pean Standard EN 13544-1: 2007 + A1: 2009. For the aspiration f t  aerosol,  ine pump (Model
SRU500CC, VCS, Pa ma, Italy) that reproduced the respi atory act through inhalation/exhalation
us d. The volume of air moved was 500 mL with a cycle of 15 respiratory acts per minu  and with a 
ratio of inhalatio /exhalation equal to 1. The nebuliz tion time for the AOR was 1 min, while the
nebulization time for the AO was 1 min after the “spu tering”. An NaF solution in distilled water was
pr par d at a 1% (w/v) fina  concentration. The experiments ere c rried out in triplicate. 
The determination of the AOR was performed as follows: the outlet of the n bulizer system
equipped with a silico  r bber adapter was connect d to t e filter and its holder, and the latt r to
the sine pump. The ampoule wa  fill d with 2 mL of the 1% (w/v) NaF solution (to be nebulized). The
p mp was switched , and, 10 s later, so was t  li r. After 1 min, the nebulizer was switche
off, and 5 s lat r, the si e pump was, too. The filter, the filter holder, and the dismountable connect r
from the outlet of the nebulizer sys em to the filter holder were dismantled. The amount of sodium
fluoride in the components from th  outlet f the nebulizer to he filter, included, was extracted and 
measur d. Th  w shi g waters were transfe red into 50-mL volum tr c flasks cont ining 5 mL of
TISAB III soluti  and w re brought to volume with distilled water. Prior to this, he fil was wetted
in the crystallizer with distilled water and sonicated for 5 min to favor NaF recovery. 
The concentration of NaF in the volum tric flasks was etermined i  mV using an ion-selective
electrode (Cris n Strumenti S.p.A., Carpi, MO, Italy) connected to the pote t omet r (pH met
Crison GPL21 S/N 145024 (Crison Instruments S.p.A., Carpi, MO, Italy))
An analysis for the determination of the AO was carried out following the procedure described 
above, xcept for the nebulization time. The aerosol was collected in the filter inside the filter holder 
from t beginni g of nebulization until one minute after the sputtering. 
2.2.2. A rodynamic Assessment 
The aerodynamic parameters (MMAD, GSD, and FPF) were determined according to the 
method described in the European Standard EN 13544-1: 2007 + A1: 2009. A next-generation impactor
(NGI, Copley S/N NGI-0497 (C pley Scientific Limited, N ttingham, UK)) was used. The
experiments were performed in triplicate. 
The NGI w s con cted to n Erweka pump (model VP1000 S/N 1 161406a7 (Erweka I alia
S.R.L., S veso, MB, Italy) via the solenoid valve of the critical flow controller (model TPK. Copley
(Copley Scientific Limit d, Nottingham, UK)). The NGI induction port was connected to the T-shap d
gl s tube using a silicone rubber adap er. A continuous aspiration flo  of 15 L/min measured at the
T-t be ebulizer port (Flow eter Mod l DMF 2000; Co ley Sci ntific Limited, Nottingham, UK) was
pplied f r aerosol col ction in the NGI. The mouthpiece of the ampoule, attached to the nebulizer,
was connected to the T-shaped glass tube. The ampoule was filled with 2 mL of 2.5% (w/v) NaF 
solution. The nebulization time was fixed at 120 s, except for the nebulizers Pari Boy Sx ( lue pisper)
nd Omron A3 C mplete (p sition 1), in which it was 90 s and 45 s, respectively, due to a short r
sputtering time. 
The Erweka pump and the TPK valve were switched on, and after 30 s, the nebulizer was 
activated. The aerosol was collected during the predetermined nebulization time in the NGI stages 
* nebulizer nozzle.
2.2.2. Aerodynamic Assessment
The aerodynamic p ameters (MMAD, GSD, and FPF) were det mined according to the method
described in t e European Standard EN 13544-1: 2007 + A1: 2009. A n xt-generat on impactor (NGI,
Copley S/N NGI-0497 (Copley Scientific Limited, Nottingh m, UK)) was used. The experime ts were
perform d in tr plicat .
The NGI was connected to an Erweka pump (model VP1000 S/ 11161406a7 (Erw ka Italia S.R.L.,
Seveso, MB, Italy) via the solenoid valve of th critical flow contr ller (model TPK. Copley (Copley
Scientific Limi ed, Notting am, UK)). Th NGI induction port was connected to the T-sh ped glass
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tube using a silicone rubber adapter. A continuous aspiration flow of 15 L/min measured at the
T-tube nebulizer port (Flowmeter Model DMF 2000; Copley Scientific Limited, Nottingham, UK) was
applied for aerosol collection in the NGI. The mouthpiece of the ampoule, attached to the nebulizer,
was connected to the T-shaped glass tube. The ampoule was filled with 2 mL of 2.5% (w/v) NaF solution.
The nebulization time was fixed at 120 s, except for the nebulizers Pari Boy Sx (blue pisper) and Omron
A3 Complete (position 1), in which it was 90 s and 45 s, respectively, due to a shorter sputtering time.
The Erweka pump and the TPK valve were switched on, and after 30 s, the nebulizer was activated.
The aerosol was collected during the predetermined nebulization time in the NGI stages (1–7) and
a micro-orifice collector (MOC), upon which a filter was placed. The nebulizer was switched off,
and after 5 s, the Erweka pump and TPK valve were also switched off.
The ampoule, mouthpiece, silicone rubber adapters, T-shaped glass tube, induction port,
NGI stages (1–7), and filter on the MOC were washed with distilled water, and the washing waters
were transferred into 50-mL volumetric flasks each containing 5 mL of TISAB III solution and brought
to volume with distilled water. Prior to this, the filter was wetted with distilled water in the crystallizer
and sonicated for 5 min to favor NaF recovery. The concentration of NaF in the volumetric flasks was
determined in mV using an ion-selective electrode connected to the potentiometer.
NaF standard solutions in the range of 10−5–10−1 mol/L were prepared for the construction of the
calibration curve, which was used for the determination of fluoride with an ion-selective electrode.
2.2.3. Data Processing
The values for the AOR, AO, MMAD, and FPF were determined using Excel and KaleidaGraph
(Sinergy Software v.4.5.2, Sinergy Software, Reading, PA, USA).
3. Results and Discussion
According to the European Pharmacopoeia (Ph. Eur.), products intended for pulmonary
administration by nebulization are tested with respect to the total amount of active substance
delivered, the delivery rate, and the aerodynamic assessment of the nebulized aerosol [28]. These tests
focus on the biopharmaceutical aspects of drug delivery. However, the same tests are used for the
technical assessments of the nebulizer performance, typically regulated by the appropriate European
Standard (whose code contains the letter EN). Since the products for nebulization require a combination
of formulation and nebulizer, drug availability essentially depends on the formulation’s interaction
with the selected nebulizer. It is not surprising that the same formulation is aerosolized differently
in different nebulizers. The nebulizer’s performance is expressly regulated by the EN Standard on
Respiratory Therapy Equipment [27]. The proposed use of NaF solution, as a surrogate for drug
formulation, has the aim of standardizing the impact of the drug formulation on the nebulization
performance. Thereby, the effect of the nebulizer on the aerosol delivery becomes apparent.
In characterizing the nebulization product, the drug emitted to the patient, measured as total
output or drug delivered during a number of inhalation/exhalation cycles, is the quantitative parameter.
The fine particle fraction is the qualitative parameter, i.e., the aerosol fraction having an aerodynamic
diameter lower than 5 µm. Its measurement provides the aerosolized drug fraction at the size
appropriate for deposition into the lungs. The third parameter, indicated by Ph. Eur. and EN, i.e.,
the output rate, is relative to the kinetics of nebulization: it is the amount of drug emitted in one minute
of nebulization, usually the first minute.
The three nebulization parameters are decisive for in vivo drug disposition since they are
bioavailability contributors. The respirable output obtained by multiplying the total output per the
respirable fraction identifies the amount of drug potentially absorbable: it is reasonable to relate this
parameter to a drug plasma profile measurable as systemic exposure (area under the curve (AUC)) [29].
It is known that the second determinant of bioequivalence (BE), i.e., the rate of absorption, derives
from onsite drug dissolution and permeability. In the case of nebulization, the time of administration
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is generally shorter than 10 min. In oral drug administration, a dissolution time less than 15 min is
considered to have no significant influence on BE.
Thus, the rate of absorption can barely be significantly affected by the time for aerosol deposition.
Only in the case of prolonged release formulations, a slow drug release, and absorption could the
plasma profile be affected; however, also in this case, the absorption rate’s dependence on the time of
aerosol inhalation is improbable, since this time is quite short. In summary, the nebulization time has
to be considered a marginal variable in the drug absorption rate.
In Figure 1, the times required (AO time) to nebulize 2 mL of NaF solution are ranked for all of
the tested jet nebulizers (operated according to the manufacturers’ instructions): some of them were
used in different ampoule settings.Pharmac utics 2019, 11, x FOR PEER REVIEW 5 of 10 
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In the other panels of Figure 1, the measured values of the AOR, AO, and FPF are illustrated
as well by ranking the values obtained in a descending order. Comparing the panels of the figure,
the different nebulizers tested under the same conditions did not rank in the same order for all of the
parameters considered.
The resulting MMADs are reported in Table 2. As the MMAD increased, the FPF decreased.
Table 2. MMAD (mass median aerodynamic diameter) and GSD (geometric standard deviation) (mean
± standard deviation, n = 3) resulting from nebulization of NaF solution with the selected nebulizers.
Nebulizer Configuration MMAD (µm) GSD
Pari Compact 3.21 ± 0.15 2.27 ± 0.03
Pari Compact Junior 3.38 ± 0.19 2.22 ± 0.01
Pari Boy SX Blue Pisper 3.48 ± 0.09 2.21 ± 0.03
Red Pisper 2.56 ± 0.12 1.99 ± 0.02
Pari Junior Boy SX 3.14 ± 0.12 2.10 ± 0.04
Pari Turbo Boy SX 3.67 ± 0.20 2.19 ± 0.05
Microdrop Family 2 3.65 ± 0.07 2.12 ± 0.01
Microdrop Calimero 2 Ampoule Valve MAX 3.28 ± 0.09 2.19 ± 0.03
Ampoule Valve MIN 2.90 ± 0.03 2.22 ± 0.05
Microdrop Pro 2 Ampoule Valve MAX 3.14 ± 0.06 2.10 ± 0.02
Ampoule Valve MIN 2.84 ± 0.07 2.10 ± 0.05
Microdrop Pro 2 Plus Ampoule Valve MAX 2.47 ± 0.09 2.02 ± 0.03
Ampoule Valve MIN 2.14 ± 0.08 2.12 ± 0.02
Omron C801KD 3.25 ± 0.15 2.04 ± 0.02
Omron NE-C28P 3.63 ± 0.12 2.05 ± 0.03
Omron A3 Complete Ampoule Position 1 6.76 ± 0.16 2.54 ± 0.02
Ampoule Position 3 4.44 ± 0.06 2.12 ± 0.03
Midineb Nebby 4.97 ± 0.01 2.16 ± 0.03
In addition, through an attentive analysis of the data, one can see that the aerosol quality correlated
with the nebulization rate. In fact, plotting the FPF versus the AO time, the quality of the nebulization
significantly increased when the rate of aerosol emission decreased (Figure 2).
The plot of Figure 2 shows the significance level of correlation considering the values collected
from all of the nebulizers. The contribution of the individual nebulizer to this relationship could
be evidenced by grouping the values exhibited by the nebulizers belonging to the same apparatus
manufacturer. Figure 3 shows the FPF versus the time of nebulization for the apparatuses manufactured
by Pari, Omron, and Flaem. A greater influence of the nebulization rate on the FPF for the Pari and
Omron nebulizers than for the Flaem nebulizers was observed.
In summary, the nebulization rate of the same amount of solution aerosolized can have a significant
effect on the respirability of the aerosol. In general, a decrease in the fine particle fraction was observed
when the time of aerosolization was shortened. However, this negative effect can be counteracted by
the technology developed in the nebulizer.
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The EN parameters presented in Figure 1 are frequently combined in an attempt to compare the
different nebulizers in a more comprehensive manner. For example, some authors have calculated the
respirable dose delivery rate parameter (RDDR) together, multiplying the aerosol output rate by the
fine particle fraction [30]. Other researchers have preferred to quantify the total respirable delivered
dose (RDD) by multiplying the aerosol output by the FPF [8]. Substantially, these two combined
parameters have different biopharmaceutical meanings, since the first is related to the deposition
rate of respirable aerosol, whereas the second represents the amount of respirable aerosol deposited.
Therefore, they differently evaluate the performance of a nebulizer, characterizing nebulization as the
rate and amount of respirable product deposited into the lungs.
We have already anticipated that the rate of drug deposition during nebulization per se has to
be considered slightly influential on the rate of bioavailability (absorption). The time interval of the
inhalation a ministration is too short for highlighting differences in BE. More likely, this parameter
char cterizes the time of nebulization t at is relevant to the patient’s c nvenience. Alternatively,
t e RDD relates to drug exposure, which in the case of drug bsorption d termines the area under the
plasma profile.
The combined parameters measuring the respirable dose delivery rate (RDDR) and the total
respirable delivered dose (RDD) were calculated from the data repo ted in Figure 1. The values are
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Figure 4. Respirable dose delivery rate (RDDR) and the total respirable delivered dose (RDD) ranked
accordingly to the nebulizer used (mean value ± standard deviation, n = 3).
Comparing the two bar graphs, evidence emerged that the various nebulizers ranked differently
depending on their characteristics, which was evidenced by the combined parameter considered.
This does not indicate that one nebulizer is better than another one, since each nebulizer works in
combination with the specific formulation it delivers. The authors do not intend to generalize or
claim superiority, since it is clear that the most significant parameter to take into account in nebulizer
performance is strictly related to drug activity and formulation combined. The bar graphs only have
the meaning of ranking the characteristics of jet nebulizer product depositions in terms of rate and
“extent” of the respirable delivered aerosol, using a standard NaF solution as formulation.
4. Conclusions
The rate and extent of drug absorption from dosage forms are the determinants of drug
bioequivalence. The nebulization time determines the total respirable dose deposited and, in the case of
absorption, it is proportional to the AUC of the drug plasma profile. In the usual conditions of nebulizer
usage, the rate of drug absorption after nebulization is marginally affected by the nebulization time.
Due to patient convenience reasons, extending the nebulization time in order to control the absorption
rate is not comparable to a drug release control after oral administration of a sustained release product.
The parameters RDDR or RDD, here presented for a large group of jet nebulizers, offer to
healthcare provid rs relevant information on th appropriat use of apparatuses. The user can
selec the nebulizer characteristics depe ding on drug properties, therapy needs, patient respiration
characteristics, and results nee d. Dru activity and th herapeutic obj ctive of nebulizat on directs
the nebulizer choice for herapy effectiveness (provid d by th rate and “extent” of nebulization).
Finally, it should be underlined that this study was conducted with a standard formulation, i.e.,
a sodium fluoride solution. Using an actual drug formulation, the performances could substantially
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change the results illustrated, since a nebulized aerosol is the result of a combination of an apparatus
and a formulation.
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